Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

“Patients taking compounded tirzepatide injection are going to need to be transitioned to the FDA-approved drug Mounjaro or Zepbound,” Brunner said. “In many instances, it’s going to take ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

Mounjaro and Zepbound are both names for the ... Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic versions on the market. But when the drug ...

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

Eli Lilly, the manufacturer of Mounjaro and Zepbound, has clearly stated that any drugs sold online or elsewhere under the name “tirzepatide,” which contain only tirzepatide, are not FDA ...

The Sept. 30 decision by the FDA endangered the ability of compounders to sell versions of Lilly's weight loss drug Zepbound and diabetes drug Mounjaro. The FDA decision removed their active ...

The FDA has said it has agreed to reconsider its ... which is sold by Lilly as Mounjaro for diabetes and Zepbound for obesity, have actually been resolved, as reported earlier this month.

The Food and Drug Administration on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, sold as Mounjaro for ... agency guidelines, the FDA warned at the time ...

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss ...